Search PubMed⌕ Search

Biomedical subjects

L Thuesen

Publications and source records attributed to L Thuesen.

At least 37 records · Page 2Linked to original sources
PubMed1997

[Stent implantation in genuine coronary vessels--with and without guidance of intracoronary ultrasound].

The purpose of the present study was to evaluate the clinical and angiographic results of implantation of stents in the native coronary circulation. In group A (n: 33) implantation was assessed by angiography, in group B (n: 17) also by ICUS. There were no procedure related deaths, transmural myocardial infarctions or acute coronary by-pass operations (CABG). The diameter of stenosis before treatment was 86% and 82% in group A and B, respectively. In both groups an overdilatation was seen following stent implantation, 5% in group A versus 22% in group B (p < 0.01). At four months follow-up 80% in group A and 81% in group B were symptom-free or improved (NS). Angiographic restenosis (> or = 50% reduction of vessel diameter) was found in 10.3% in group A versus 20.0% in group B (NS). Our results are in accordance with other coronary stent studies showing reduced acute coronary occlusion and CABG incidence and a low restenosis rate as compared to conventional balloon angioplasty. The role of ICUS in the implantation of intracoronary stents remains unsettled.

Adult↗
PubMed1996

[Sick sinus syndrome. Pacemaker with atrial versus ventricular stimulation].

In patients with sick sinus syndrome, single chamber atrial pacing has been reported in retrospective studies to be associated with lower frequencies of atrial fibrillation, thromboembolism, heart failure, and mortality than ventricular pacing. We did a prospective randomised trial in 225 consecutive patients (142 women, 83 men; mean age 76 years) with the sick sinus syndrome, randomised to atrial (n = 110) or ventricular (n = 115) pacing and followed for up to five years (mean 40 [SD 18] months). During follow-up, the frequency of atrial fibrillation was higher in the ventricular group. Thromboembolic events (stroke or peripheral arterial embolus) occurred in 20 patients in the ventricular group and in six patients in the atrial group (p = 0.008). Twenty five patients died in the ventricular group compared with 21 in the atrial group (p = 0.74). The number of cases of heart failure did not differ between the two groups. Atrioventricular block occurred in two patients in the atrial group. It is concluded that patients with sick sinus syndrome should be treated with atrial pacing rather than ventricular pacing because atrial pacing is associated with lower frequencies of atrial fibrillation, thromboembolic complications, and a low risk of atrioventricular block.

Aged↗
PubMed1996

Growth hormone versus placebo treatment for one year in growth hormone deficient adults: increase in exercise capacity and normalization of body composition.

OBJECTIVE: Studies with GH substitution in GH-deficient (GHD) adults lasting more than 6 months have so far been uncontrolled. End-points such as physical fitness and body composition may be subject to a considerable placebo effect which weakens the validity of open studies. We therefore tested GH (2 IU/m2 per day) versus placebo treatment for 12 months. DESIGN: Twenty-nine patients (mean age 45.5 +/- 2.0 years) with adult-onset GHD were studied in a double-blind, parallel design. Measurements of body composition by means of conventional anthropometry, bioelectrical impedance (BIA), CT scan and DEXA scan, exercise capacity, and isometric muscle strength were performed at baseline and after 12 months treatment. For body composition measurements a control group of 39 healthy, age and sex-matched subjects was included. RESULTS: Sum of skinfolds (SKF) at 4 sites decreased significantly after GH treatment. Total body fat (TBF) as assessed by DEXA and BIA was elevated at baseline but normalized after GH. TBF assessed by SKF revealed significantly higher levels compared to DEXA and BIA, although all estimates intercorrelated closely. Visceral and subcutaneous abdominal fat decreased by 25 and 17%, respectively after GH (P < 0.01) to levels no longer different from the control group. CT of the mid thigh revealed a significant reduction in fat tissue and a significant increase in muscle volume after GH treatment, both of which resulted in a normalization of the muscle: fat ratio (%) (placebo: 58:42 (baseline) vs 58:42 (12 months); GH: 66:34 (baseline) vs 72:28 (12 months) (P = 0.002); normal subjects: 67:33 (P < 0.05 when compared to 12 months placebo data)). Total body resistance and resistance relative to muscle volume decreased significantly after GH treatment suggesting over-hydration as compared to normal subjects. Exercise capacity (kJ) increased significantly after GH treatment (placebo: 54.7 +/- 9.8 (baseline) vs 51.6 +/- 8.2 (12 months); GH: 64.9 +/- 13.3 (baseline) vs 73.5 +/- 13.6 (12 months) (P < 0.05)). Isometric quadriceps strength increased after GH but no treatment effect could be detected owing to a small increase in the placebo group. Serum IGF-I levels (microgram/l) were low baseline and increased markedly after GH treatment to a level exceeding that of normal subjects (270 +/- 31 (12 months GH) vs 156 +/- 8 (normal subjects (P < 0.01)). The levels of serum electrolytes and HbA1c remained unchanged. The number of adverse effects were higher in the GH group after 3 months, but not after 6 and 12 months. CONCLUSIONS: (1) The reduction in excess visceral fat during GH substitution is pronounced and sustained; (2) beneficial effects on total body fat, muscle volume and physical fitness can be reproduced during prolonged placebo-controlled conditions; (3) uncontrolled data on muscle strength must be interpreted with caution; (4) a daily GH substitution dose of 2 IU/m2 seems too high in many adult patients.

Abdomen↗
PubMed1995

[Percutaneous removal of an in-situ embolised catheter fragment in a patient with Port-A-Cath].

The totally implantable catheter system has gained popularity as venous access when prolonged treatment is needed. It has several advantages over other methods of venous access, such as less discomfort for the patient, and a decreased rate of complications. A case with an uncommon but potentially serious complication, i.e. spontaneous intravascular fracture of the outlet catheter, is reported. The distal fragment of the catheter migrated into the right ventricle of the heart. The embolized fragment was removed percutaneously with a snare catheter. Causes of catheter fracture are discussed, and recommendations for implantation and radiological control are outlined.

Cardiac Catheterization↗
PubMed1995

[Intracoronary ultrasonography--a supplement to coronary arteriography].

Intracoronary ultrasound is a new technique, by means of which it is possible for the first time to visualise coronary artery wall structures in vivo. Compared to conventional coronary angiography the advances of this new modality appear to be: 1) Improved diagnosis of minimal and non-obstructive atherosclerosis; 2) Characterisation of plaque morphology, thereby being an aid in decision on interventional procedures (PTCA, atherectomy, stent placement); 3) Better delineation of coronary artery lumen area, which improves the accuracy of stenosis graduation both before and after interventional procedures. The examination can be performed in up to 95% of cases. The procedure appears to be safe with a reported complication rate of myocardial infarction and bypass surgery of 0.16% in 1837 cases; transient coronary artery spasms occurred in about 3%. Complications are predominantly associated with interventional procedures. Although intracoronary ultrasound has mainly been used for research purposes, results of ongoing trials assessing its clinical utility, as well as technological improvement providing more consistent image quality, suggest that the procedure will evolve into an important adjunct to coronary angiography.

Coronary Angiography↗
PubMed1995

[Ambulatory coronary arteriography].

Based upon hospital files and a questionnaire we assessed the patient safety of and the patient attitude towards outpatient coronary angiography (CAG). A total of 115 consecutive patients were included in the study. Thirty two of the patients (28%) were admitted following the angiography, while 83 (72%) were discharged to the home as planned. Of those de facto ambulatory patients one (1%) was readmitted because of a groin haematoma. Of those who returned the questionnaire, 93% of the patients admitted and 97% of the de facto ambulatory patients were satisfied with the level of information, and 76% and 99%, respectively, would prefer out-patient CAG to CAG during admission. We conclude that out-patient CAG can be performed with a very low risk and is well accepted by the patients.

Adult↗
PubMed1994

Prospective randomised trial of atrial versus ventricular pacing in sick-sinus syndrome.

In patients with sick-sinus syndrome, single-chamber atrial pacing has been reported, in retrospective studies, to be associated with lower frequencies of atrial fibrillation, thromboembolism, heart failure, and mortality than ventricular pacing; although single-chamber ventricular pacing is most commonly used. We did a prospective randomised trial in 225 consecutive patients (142 women, 83 men; mean age 76 years) with the sick-sinus syndrome, randomised to atrial (n = 110) or ventricular (n = 115) pacing and followed for up to 5 years (mean 40 [SD 18] months). During follow-up, the frequency of atrial fibrillation was higher in the ventricular group, except at the first follow-up at 3 months. Thromboembolic events (stroke or peripheral arterial embolus) occurred in 20 patients in the ventricular group and in 6 patients in the atrial group (p = 0.0083). 25 patients died in the ventricular group compared with 21 in the atrial group (p = 0.74). Heart failure estimated by the New York Heart Association classification and by the daily doses of diuretics did not differ between the two groups. Atrioventricular block occurred in 2 patients in the atrial group. Patients with sick-sinus syndrome should be treated with atrial pacing rather than ventricular pacing because atrial pacing is associated with lower frequencies of atrial fibrillation, thromboembolic complications, and a low risk of atrioventricular block.

Aged↗
PubMed1994

Short and long-term cardiovascular effects of growth hormone therapy in growth hormone deficient adults.

OBJECTIVE: Since GH substitution therapy is now available for adult GH deficient patients, information on the cardiovascular effects of GH substitution has assumed major clinical interest. We have therefore assessed cardiovascular effects of short and long-term growth hormone substitution therapy in these patients. PATIENTS AND MEASUREMENTS: Doppler echocardiography was performed in 21 GH deficient patients after 4 months placebo and 4 months GH therapy, in a double blind cross-over study. In an open design study, 13 patients were reinvestigated following 16 months and 9 patients following 38 months of GH therapy. Twenty-one age and sex-matched normal control subjects were also investigated. RESULTS: Heart rate was increased in placebo treated patients as compared to controls. After 4 months of GH treatment, heart rate showed a further increase (10%, P < 0.01) and seemed to remain elevated after 16 months of GH therapy. Systolic and diastolic blood pressures were significantly lower in placebo treated patients than in controls, and did not change significantly after GH treatment. The left ventricular diastolic diameter was reduced in patients as compared to controls, but increased after 4 months GH therapy (P > 0.05) and seemed to increase further during prolonged GH treatment. Cardiac index was at the same level in controls and in placebo-treated patients, but increased by 20% following GH therapy and remained elevated after 16 and 38 months (P < 0.05) of GH substitution. CONCLUSION: Following GH substitution in GH deficient adult patients, left ventricular diastolic dimensions increased and seemed to normalize, while heart rate and cardiac output were found to be increased to supranormal levels.

Adult↗
PubMed1994

Three years of growth hormone treatment in growth hormone-deficient adults: near normalization of body composition and physical performance.

Growth hormone (GH) replacement therapy in several controlled short-term trials have shown unanimous beneficial effects on body composition and other features. To evaluate more long-term effects we report data from 3 years of uninterrupted GH therapy in 10 GH-deficient adults who had all completed a previous double-blind placebo-controlled study and who also had been studied after 16 months of open GH therapy. No further increase in linear height was observed. The initial increase in thigh muscle volume was maintained after 3 years of GH therapy. A slight increase in body weight and thigh fat volume was recorded. Exercise capacity and isometric muscle strength were increased significantly compared to the initial placebo period. This was associated with stabilized levels of resting heart rate and blood pressure. Glycosylated hemoglobin levels were normal and did not change during the study. A standard oral glucose tolerance test performed at the end of the study revealed no evidence of glucose intolerance. No side-effects were reported. Compared to an age- and sex-matched group of healthy untreated subjects, thigh muscle volume, exercise capacity and isometric muscle strength had become normalized from subnormal levels after 3 years of GH therapy. We conclude that long-term GH replacement therapy in GH-deficient adults is associated with preserved beneficial effects on body composition and physical performance, resulting in a near normalization of several previously abnormal features and adding new merits to this treatment modality.

Adult↗
PubMed1994

Short- and long-term survival after aortic balloon valvuloplasty for calcified aortic stenosis in 137 elderly patients.

UNLABELLED: Percutaneous transluminal balloon aortic valvuloplasty was performed in 137 patients with symptomatic severe calcified aortic stenosis (50 men and 87 women, mean age 77 years) between December 1986 and September 1990. The purpose of the study was to evaluate short- and long-term survival after balloon aortic valvuloplasty, mean follow-up was 19 months. At the time of balloon aortic valvuloplasty congestive heart failure (NYHA III-IV) was present in 89%, angina pectoris in 47%, and syncope in 31% of the patients. Aortic balloon dilatation produced significant decreases in peak pressure gradient from 91 +/- 34 mmHg to 40 +/- 26 mmHg (p < 0.001). The procedure related mortality was 8% (11 pts) and the 30-days mortality 17% (23 pts). Severe complications occurred in 25% of the patients during the procedure and within the first 24 hours. Immediate clinical improvement was noted in 68% of the patients surviving the treatment. The overall survival rate was at one, two, three and four years follow-up 63%, 40%, 28%, and 21%, respectively. These survival rates were all statistically different from the survival rates in an age- and sex-matched background population (p < 0.001). A multivariate Cox analysis revealed that only female sex and angina before treatment seemed to improve survival. CONCLUSION: The long-term outcome after aortic balloon valvuloplasty for severe aortic stenosis is so poor that we recommend aortic valve replacement as the initial treatment in these patients, if at all possible.

Adult↗
PubMed1994

[Heart involvement in HIV infection].

Postmortal examinations have shown cardiac involvement in more than 50 percent of patients with AIDS. Echocardiographic studies have shown exudative pericarditis in 18-38 percent of patients with AIDS. The pericardial effusion is usually without haemodynamic consequence, but may be associated with cardiac tamponade. Dilation and hypokinesia of the left ventricle have been found in 30 per cent of patients with AIDS. The impairement of the left ventricular function is primarily seen in febrile, severely diseased AIDS patients, while ambulatory HIV-positive patients have a low prevalence of myocardial involvement. AIDS-patients should be examined by echocardiography in case shortness of breath and hypoxemia are out of proportion to the pulmonary findings.

Acquired Immunodeficiency Syndrome↗
PubMed1994

Cardiac function in patients with human immunodeficiency virus infection and with no other active infections.

OBJECTIVE: to investigate cardiac function and prognostic significance of echocardiographic findings in patients with uncomplicated human immunodeficiency virus (HIV)-infection. PATIENTS AND METHODS: Doppler echocardiography was performed in 60 male patients with HIV-infection and no signs of other active infections, and in 36 age and sex matched normal control subjects. The survival time of the patients was assessed 36 months after the echocardiographic examination. RESULTS: None of the patients had significant pericardial effusions, intracardiac tumors, signs of valvular endocarditis or dilated cardiomyopathy. In none of the patients were the fractional shortening or the early and atrial mitral flow ration (E/A ratio) below the 95% confidence limit of the control group. The E/A ratio was slightly, but significantly, decreased in AIDS patients both as compared to asymptomatic HIV-infected patients and as compared to normal control subjects because of increased heart rated in the AIDS patients. Within the three-year observation period, 28 of the patients died from HIV-related disease. In the group of deceased patients, there was no significant correlation between blood pressure, heart rate, left ventricular diameters, fractional shortening, E/A ratio and the survival time. CONCLUSION: In a population of HIV-infected patients with no other active infections, cardiac abnormalities seen to be uncommon, and the echocardiographic fractional shortening and E/A ratio were not related to the survival time of such patients. Thus, our data does not evidence that HIV is a direct cardiac pathogen.

Acquired Immunodeficiency Syndrome↗
PubMed1993

Assessing the severity of aortic valve stenosis by spectral analysis of cardiac murmurs (spectral vibrocardiography). Part I: Technical aspects.

Assessing the severity of aortic stenosis remains an important clinical problem. The turbulent pressure fluctuations generated by the confined jet down-stream of the stenotic valve produce vibrations in the aortic wall. These vibrations are transmitted through the chest to the skin surface, where they can be measured as systolic ejection murmurs. The purpose of the present study was to find the relationship between the severity of aortic valve stenosis and the frequency content of the precordial systolic murmurs, and to evaluate the transthoracic attenuation of murmurs and its variation from patient to patient. Twenty-four patients with clinical signs of aortic stenosis underwent cardiac catheterization to measure the peak transvalvular pressure difference. The mean energy density spectrum of the measured systolic precordial murmurs was calculated and the murmur energy ratio between 100-500 Hz and 20-500 Hz was correlated to the transvalvular pressure difference. The inter-individual variability of the transthoracic attenuation was evaluated by calculating the transthoracic transfer function from simultaneous measurements of precordial vibrations at the second right intercostal space and intravascular recordings of high frequency pressure fluctuations in the ascending aorta. The transvalvular pressure difference and the square root of the murmur energy ratio correlated well (r = 0.81, SEE = 27 mmHg). In the frequency range from 10-500 Hz the transthoracic transfer function could be modelled by a low-pass filter function with a low frequency attenuation of 36 +/- 7.7 dB (mean +/- SD), a corner frequency of 26 +/- 12 Hz and an attenuation slope of -29 +/- 7.9 dB/decade. Spectral analysis of systolic murmurs might be an attractive non-invasive addition to the array of techniques already in use for assessing the severity of aortic stenosis. It is a simple and cost effective technique, and requires less skill and time for data analysis than conventional methods.

Adult↗
PubMed1993

Assessing the severity of aortic valve stenosis by spectral analysis of cardiac murmurs (spectral vibrocardiography). Part II: Clinical aspects.

Assessing the severity of aortic stenosis remains an important clinical problem. The turbulent pressure fluctuations generated by the jet downstream of the stenotic valve produce vibrations in the aortic wall. These vibrations are transmitted through the chest to the skin surface, where they can be recorded as systolic ejection murmurs. The purpose of the present study was to estimate the transvalvular aortic pressure difference by spectral analysis of heart murmurs (spectral vibrocardiography). Forty-four patients with clinical signs of aortic stenosis underwent cardiac catheterization to measure the transvalvular pressure difference. In a double blind prospective study, precordial vibrations were measured prior to catheterization using a dedicated heart sound analyzer (Vibrocard 2000) to calculate the spectral ratio of murmur energy between 100-500 Hz and 20-500 Hz. Three different weighting filters were used to compensate for individual differences in the transthoracic attenuation of murmurs. The square root of the murmur energy ratio correlated linearly with the mean transvalvular pressure difference (r = 0.80, SEE = 13 mmHg) and with the peak transvalvular pressure difference (r = 0.81, SEE = 16 mmHg). The use of individual compensation filters improved the correlation. This study shows that it is possible to estimate the transvalvular pressure difference in patients with aortic valve stenosis by spectral analysis of heart murmurs. It is a fast, simple and cost effective technique, which requires less skill than conventional methods.

Adult↗
PubMed1991

Long-term growth hormone treatment in growth hormone deficient adults.

Growth hormone treatment in GH-deficient adults has proved beneficial in recent short-term trials, but long-term results have not yet been reported. Thirteen GH-deficient adults (4 females, 9 males; mean (SEM) age 26.4 (1.7) years), who had completed 4 months of GH therapy in a double-blind placebo-controlled cross-over study were followed, for further 16.1 (0.8) months of uninterrupted GH therapy in an open design. A significant mean increase of 1.3 cm in linear height was recorded, whereas body mass index remained unchanged. Mean muscle volume of the thigh, estimated by computerised tomography, increased significantly compared with that of the initial placebo period (p = 0.01), and a slight decrease was recorded in adipose tissue volume of the thigh (p = 0.10) and subscapular skinfold thickness (p = 0.10). Still, the muscle to fat ratio of the thigh was significantly lower compared with that of normal subjects (72.6/27.4 vs 77.9/22.1) (p less than 0.01). The mean isometric strength of the quadriceps muscles increased significantly during long-term GH therapy (p less than 0.01), but remained lower compared with that of normal subjects (1.66 (0.10) vs 2.13 (0.11) Nm/kg body weight). Exercise capacity performed on a bicycle ergometer increased significantly after long-term therapy (p less than 0.05), but still did not reach the values seen in normal subjects (22.5 (3.4) vs 37.4 (4.2) watt.min.kg-1. No adverse reactions were recorded during long-term therapy and hemoglobin A1c remained unchanged. These data suggest that long-term GH replacement therapy in GH-deficient adults has beneficial effects on several physiological features which are subnormal in these patients.

Adult↗
PubMed1989

[Percutaneous pulmonary balloon valvuloplasty in Denmark].

Percutaneous balloon valvuloplasty of valvular pulmonary stenosis (PPB) was carried out for the first time in 1982 and is now regarded as the primary method of treatment of this condition. The results of the first PPB treatments in Denmark are presented here. PPB was planned in 28 patients and was carried out in 25 (22 children and 3 adults). PPB was carried out on two occasions in one patient. Twenty-three patients had isolated valvular pulmonary stenosis and two patients had Fallot's anomaly. No complications of significance occurred after the treatments. The average gradient for all dilatations was 77 +/- 24 mm Hg prior to and 36 +/- 23 (p less than 0.0001) immediately after PPB. The gradient was reduced by more than 50% in 68% of the patients. In 14 patients, the gradients over the pulmonary valve was measured by Doppler technique or by cardiac catheterization greater than 6 months after PPB. In these patients, the average gradient was 69 +/- 21 mm Hg prior to PPB, 29 +/- 12 mm Hg (p less than 0.0001) immediately after PPB and 27 +/- 9 mm Hg (p less than 0.0001) at the most recent control examination, on an average 12 months (range 6-24 months) after PPB. In the same patient group, significant reduction of the electrocardiographic right-sided hypertrophy was found at the most recent control examination. It is concluded that PPB is an effective and safe treatment of valvular pulmonary stenosis.

Adolescent↗